top of page


Targeting immune-mediated diseases at the root cause.

Our lead asset is a Phase 2-ready human monoclonal antibody that offers broad therapeutic potential by exploiting mechanisms that play a causal role across a wide array of immune-mediated diseases.

Leveraging the foundational strength of our lead asset, we aim to rapidly enter the clinic and create the proof-of-concept data that will support the advancement of promising therapeutic programs and the development of an expanded pipeline of de-risked drug assets.

We are focused on transforming the treatment of a broad array of immune-mediated diseases through the development and delivery of promising therapeutics.
bottom of page